E2F Decoy Treatment for Graft/Recipient Vein Stenosis in PTFE Vascular Access Grafts for Hemodialysis

This is a diagnostic study focusing on patients with chronic renal failure who require hemodialysis. It aims to understand the impact of a treatment called edifoligide (E2F Decoy) on the vein that receives a polytetrafluoroethylene (PTFE) vascular access graft, a type of artificial blood vessel used in hemodialysis. The goal is to see if this treatment can reduce the narrowing of the vein and maintain the function of the graft. This research is important as it could potentially improve the longevity and effectiveness of hemodialysis treatments for patients with chronic renal failure. In this study, participants will have their vein treated with either edifoligide (E2F Decoy) or a placebo before the PTFE vascular access graft is placed. The effect of the treatment will be assessed 6 months after enrollment. The study measures the results by looking at the degree of vein narrowing and the preservation of graft function. This helps to determine if the treatment is effective in maintaining the health of the vein and the graft.